ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Human Growth Hormone

Also written as “somatropin”, “Somatropin” and “PEG-somatropin”.

Its studies are mostly in Dwarfism, Pituitary · Turner Syndrome · Dwarfism · Growth Disorders · Genetic Diseases, Inborn, led by 15 companies.

Drug pageHuman Growth Hormone: every studyMany companies study it; this page follows only the 117 they lead. All 217 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 13, 2005117 company-led studies, 5 open or runningNext primary completion: Apr 28, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only340 open or runningphase 4since Sep 13, 2005Feb 1, 2005none ahead
Changchun GeneScience Pharmaceutical194 open or runningphase 4since Nov 27, 2014Apr 21, 2011Apr 28, 2027phase 4 · NCT07691125
Merck KGaA, Darmstadt, Germanyits history only190 open or runningphase 4since Nov 18, 2005May 13, 2004none ahead
Pfizerits history only180 open or runningphase 4since Feb 5, 2007Sep 9, 2005none ahead
Eli Lillyits history only100 open or runningphase 4since Dec 15, 2005Sep 12, 2005none ahead
LG Chemits history only40 open or runningphase 4since Nov 10, 2016Dec 29, 2005none ahead
Daewoong Pharmaceuticalits history only20 open or runningphase 3since Jan 19, 2016Sep 23, 2011none ahead
Ferring Pharmaceuticalsits history only20 open or runningphase 3since Nov 7, 2005Nov 7, 2005none ahead
Hoffmann-La Rocheits history only20 open or runningphase 4since Dec 4, 2014Mar 11, 2004none ahead
Ipsenits history only20 open or runningphase 4since Aug 24, 2011Oct 5, 2005none ahead

Also a collaborator on its studies: Merck Serono S.A.S, France, Merck Serono Co., Ltd., China, Merck Serono S.P.A., Italy, Merck Serono S.A., Geneva, Merck, S.L., Spain and BioPartners.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Changchun GeneScience Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Apr 21, 2011.

  1. Feb 1, 2015Phase 2 study in Short Stature Children Born Small for Gestational Age (SGA)NCT02375620 · 96 enrolled · China
  2. Mar 2, 2015Phase 4 study in Dwarfism, PituitaryNCT02380235 · 600 enrolled · China
  3. Sep 19, 2016Phase 4 study in Dwarfism, PituitaryNCT02908958 · 900 enrolled · China
  4. Nov 24, 2016Phase 4 study in Dwarfism, PituitaryNCT02976675 · 600 enrolled · China
  5. Mar 28, 2017Phase 2 study in Dwarfism, PituitaryNCT03104010 · 180 enrolled · China
  6. Jul 14, 20172 phase 2 studies in DwarfismNCT03255694, NCT03221088
  7. Jul 18, 2017Phase 3 study in Small for Gestational Age InfantNCT03245333 · 120 enrolled · China
  8. Jul 24, 2017Phase 4 study in Dwarfism, PituitaryNCT03249480 · 900 enrolled · China
  9. Sep 19, 2017Phase 4 study in Growth RetardationNCT03290235 · 1,500 enrolled · China
  10. Apr 28, 2018Phase 3 study in DwarfismNCT03535415 · 68 enrolled · China
  11. May 30, 2018Phase 3 study in Prader-Willi SyndromeNCT03554031 · 30 enrolled · China
  12. Jul 28, 2021Named human growth hormoneINNProposed as its International Nonproprietary Name in WHO's List 125
  13. Apr 25, 2022Phase 4 study in AchondroplasiaNCT05353192 · 39 enrolled · China
  14. Aug 9, 2023Phase 3 study in Dwarfism, PituitaryNCT06024967 · 180 planned
  15. Jul 1, 2026Phase 4 study in Short Bowel SyndromeNCT07691125 · 100 planned · China

Ahead

  1. Apr 28, 2027Primary completion: phase 4 study in Short Bowel SyndromeNCT07691125
  2. Jun 2030Primary completion: phase 2 study in DwarfismNCT03255694

TargetBeta

GHR →read by rule
“Growth hormone receptor agonist”ChEMBL 37, by rule

Other programs on GHR

ProgramCompanyFurthest phaseStudies
lonapegsomatropinruleascendis-pharma-endocrinology-division-a-sphase 36

Studies

All 19 Changchun GeneScience Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07691125Short Bowel Syndrome · China4RecruitingApr 28, 2027100
NCT06024967Dwarfism, Pituitary3Not yet recruitingMay 1, 2025180
NCT05353192Achondroplasia · China4CompletedAug 25, 202539
NCT03554031Prader-Willi Syndrome · China3UNKNOWNJan 202030
NCT03535415Dwarfism · China3UNKNOWNSep 202068
NCT03290235Growth Retardation · China4UNKNOWNOct 20201,500
NCT03249480Dwarfism, Pituitary · China4UNKNOWNAug 2017900
NCT03245333Small for Gestational Age Infant · China3UNKNOWNDec 2017120
NCT03255694Dwarfism · China2Active, not recruitingJun 2030360
NCT03221088Dwarfism · China2UNKNOWNDec 2018360
NCT03104010Dwarfism, Pituitary · China2UNKNOWNFeb 2022180
NCT02976675Dwarfism, Pituitary · China4UNKNOWNJun 2017600
NCT02908958Dwarfism, Pituitary · China4UNKNOWNJun 2017900
NCT02380235Dwarfism, Pituitary · China4UNKNOWNJun 2017600
NCT02375620Short Stature Children Born Small for Gestational Age (SGA) · China2Active, not recruitingDec 12, 202396
NCT02314676Dwarfism, Pituitary · China4UNKNOWNJul 2017900
NCT01613573Dwarfism, Pituitary1CompletedOct 201012
NCT01495468Dwarfism, Pituitary · China3CompletedJan 2008343
NCT01342146Dwarfism, Pituitary2CompletedJan 2007101

How it is read

Names in the registry

  • “somatropin”, 52 entries
  • “Somatropin”, 27 entries
  • “PEG-somatropin”, 13 entries
  • “Saizen®”, 6 entries
  • “Genotropin”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.